![]() |
Consilium Strategic Communications is handling the merger of Oculis and European Biotech Acquisition Corp. in a SPAC deal valued in the $220M range. The combined entity will trade on the NASDAQ.
Switzerland-based Oculis is a biopharma company focused on developing treatments to save sight and improve eye care.
Riad Sherif, Oculis CEO, said proceeds from the EBAC transaction will be used to accelerate development of drugs in its pipeline.
EBAC has screened over 100 European biotech companies.
CEO Eduardo Bravo called Oculis a prime example of what his company wants to invest in.
He said Oculis has “great innovation, a well thought-out strategy and an experienced management team to bring promising therapies to market for patients suffering from eye disease.”
Oculis has product candidates to treat macular edema, dry eye disease and nero-retina indicators such as glaucoma.
Consilium Strategic Communications, which works in the healthcare PR and IR space, has Amber Fennell, Matthew Cole and David Daley working the Oculis deal.


C Street Advisory Group handles The Children’s Place as one of the only pure-play children’s specialty retailers files for Chapter 11 and plans to sell its more than 500 outlets.
Joele Frank handles HealthSpan Partners as it ups its $25 per share offer for Surgery Partners, which uses FTI Consulting for strategic communications counsel.
Wendy’s has turned to Collected Strategies as it rejects what it calls an inadequate, unsolicited and non-binding takeover bid from a group led by Nelson Peltz’s Trian Partners.
Collected Strategies and AdvisRy Partners will handle Kaz Resources when it goes public in a $2B deal during the first half of next year.
FGS Global handles Marvell Technology as the semiconductor giant agrees to acquire Lumentum, a Joele Frank client, in all all-stock transaction worth $115B.



